Efficacy of Pirfenidone versus placebo in Idiopathic Pulmonary Fibrosis progression:a randomize clinical trial
Phase 2
- Conditions
- Idiopathic Pulmonary Fibrosis.Interstitial pulmonary disease, unspecified
- Registration Number
- IRCT2017031333044N1
- Lead Sponsor
- Vice chancellor for research, Shahid Behesti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1-Confirmed Idiopathic Pulmonary Fibrosis with lung biopsy
2-UIP view in lung HRCT with unknown cause base of ATS-ERS criteria
3-Agreement to participate in this study
Exclusion criteria:
1-Suffering from connective tissue disease
2-occupational exposure to substances that cause lung fibrosis
3-close contact with animals
4-Deny to participate in this study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total Lung Capacity. Timepoint: Before the intervention, three months after the intervention and six months after intervention. Method of measurement: Body box.
- Secondary Outcome Measures
Name Time Method Functional Lung Capacity. Timepoint: Before the intervention, three months after the intervention and six months after intervention. Method of measurement: Body box.;SPO2. Timepoint: Before the intervention, three months after the intervention and six months after intervention. Method of measurement: Body box.;DLCO. Timepoint: Before the intervention, three months after the intervention and six months after intervention. Method of measurement: Body box.